[Effect of interferon on the course of experimental E coli-induced pyelonephritis]. 1990

A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina

The effect of the type I interferon on the development and process of experimental pyelonephritis caused by E. coli was studied on mice weighing 12 to 14 g. Interferon was administered intraperitoneally in a dose of 1000 units on days 3 and 7 of the disease. It was shown that the administration of the type I interferon to the mice with experimental pyelonephritis promoted rapid elimination of bacteria from the kidneys, prevented their penetration to the contralateral (intact) kidney, prevented marked macro- and microscopic damages in the kidneys, lowered the intensity of the inflammatory reaction, and increased the phagocytic activity of neutrophils and the number of the E-rosette-forming lymphocytes in the thymus. The data provided experimental grounding for clinical trials of interferon preparations in treatment of bacterial pyelonephritis.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007682 Kidney Pelvis The flattened, funnel-shaped expansion connecting the URETER to the KIDNEY CALICES. Renal Pelvis,Pelvis, Kidney,Pelvis, Renal
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011704 Pyelonephritis Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA. Necrotizing Pyelonephritis,Pyelonephritis, Acute Necrotizing,Pyelonephritides
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012397 Rosette Formation The in vitro formation of clusters consisting of a cell (usually a lymphocyte) surrounded by antigenic cells or antigen-bearing particles (usually erythrocytes, which may or may not be coated with antibody or antibody and complement). The rosette-forming cell may be an antibody-forming cell, a memory cell, a T-cell, a cell bearing surface cytophilic antibodies, or a monocyte possessing Fc receptors. Rosette formation can be used to identify specific populations of these cells. Immunocytoadherence,Formation, Rosette,Formations, Rosette,Immunocytoadherences,Rosette Formations
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
August 1971, Clinical science,
A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
October 1964, Casopis lekaru ceskych,
A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
September 1972, Infection and immunity,
A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
February 1992, Biochemistry international,
A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
April 1988, Zeitschrift fur Urologie und Nephrologie,
A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
January 1979, Arzneimittel-Forschung,
A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
December 1968, Casopis lekaru ceskych,
A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
January 1973, Urologia internationalis,
A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
October 1969, Arzneimittel-Forschung,
A V Rudenko, and V G Maĭdannik, and V A Pavlenko, and N Ia Spivak, and A M Romanenko, and E M Ishchenko, and L P Glebova, and E N Bavina
March 1965, Virchows Archiv fur pathologische Anatomie und Physiologie und fur klinische Medizin,
Copied contents to your clipboard!